This paper presents a new three-phase phase-locked loop (PLL) system that primarily estimates the phase angles, frequency, and magnitudes of the a three-phase input signal and also provides a filtered ...

The main objective of this paper is to simplify the implementation of continuous and discontinuous 3-D space vector pulsewidth modulations (SVPWMs). This paper analyzes the relationships, whether in ...

Firmware supporting the Application Note AN3607 'Phase Sequence Detection of Three Phase AC Supply'. This application demonstrates phase sequence detection, RMS voltage measurement on the three-phase ...

Introduction Genetic and clinical evidence has shown that interleukin-33 plays a key role in the susceptibility and progression of asthma. The phase 2a FRONTIER-3 study ([NCT04570657][1]) investigated ...

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

Phase two started in November 2023, with construction of the detention basin. It will feature walk paths, lighting, benches, and landscape features. Costs were estimated at almost $40 million.

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.

In potential good news for Prothena, Roche announced earlier this week that it will advance Prothena-partnered prasinezumab into phase 3 trials for early-stage Parkinson’s disease, despite the ...

Novo Nordisk (NYSE: NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance ...

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its ...

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...

The approval decision is expected to occur by the end of 2025.Verrica expects to dose the first patient in the global Phase 3 program in the United States in the fourth quarter of 2025.Torii will ...